Literature DB >> 28110649

Mass Spectrometry Imaging in Oncology Drug Discovery.

R J A Goodwin1, J Bunch2, D F McGinnity3.   

Abstract

Over the last decade mass spectrometry imaging (MSI) has been integrated in to many areas of drug discovery and development. It can have significant impact in oncology drug discovery as it allows efficacy and safety of compounds to be assessed against the backdrop of the complex tumour microenvironment. We will discuss the roles of MSI in investigating compound and metabolite biodistribution and defining pharmacokinetic -pharmacodynamic relationships, analysis that is applicable to all drug discovery projects. We will then look more specifically at how MSI can be used to understand tumour metabolism and other applications specific to oncology research. This will all be described alongside the challenges of applying MSI to industry research with increased use of metrology for MSI.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  PK/PD; drug delivery; microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28110649     DOI: 10.1016/bs.acr.2016.11.005

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  5 in total

Review 1.  Restriction of drug transport by the tumor environment.

Authors:  Rajender Nandigama; Berin Upcin; Bertal H Aktas; Süleyman Ergün; Erik Henke
Journal:  Histochem Cell Biol       Date:  2018-10-25       Impact factor: 4.304

2.  Chemical reactivity and bioactivity properties of pyrazinamide analogs of acetylsalicylic acid and salicylic acid using conceptual density functional theory.

Authors:  Al Rey Villagracia; Hui Lin Ong; Faith Marie Lagua; Glenn Alea
Journal:  Heliyon       Date:  2020-06-23

3.  Potential Therapeutic Target Protein Tyrosine Phosphatase-1B for Modulation of Insulin Resistance with Polyphenols and Its Quantitative Structure-Activity Relationship.

Authors:  Prangya Rath; Anuj Ranjan; Arabinda Ghosh; Abhishek Chauhan; Manisha Gurnani; Hardeep Singh Tuli; Hamza Habeeballah; Mustfa F Alkhanani; Shafiul Haque; Kuldeep Dhama; Naval Kumar Verma; Tanu Jindal
Journal:  Molecules       Date:  2022-03-29       Impact factor: 4.411

4.  Synthesis, in vitro Antileishmanial Efficacy and Hit/Lead Identification of Nitrofurantoin-Triazole Hybrids.

Authors:  Nonkululeko H Zuma; Janine Aucamp; Maryna Viljoen; David D N'Da
Journal:  ChemMedChem       Date:  2022-05-02       Impact factor: 3.540

5.  Yale School of Public Health Symposium on tissue imaging mass spectrometry: illuminating phenotypic heterogeneity and drug disposition at the molecular level.

Authors:  Georgia Charkoftaki; Nicholas J W Rattray; Per E Andrén; Richard M Caprioli; Steve Castellino; Mark W Duncan; Richard J A Goodwin; Kevin L Schey; Sheerin K Shahidi-Latham; Kirill A Veselkov; Caroline H Johnson; Vasilis Vasiliou
Journal:  Hum Genomics       Date:  2018-02-27       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.